Ionis Pharmaceuticals (LTS:0JDI) Other Current Liabilities : $31.5 Mil (As of Mar. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Other Current Liabilities?

Ionis Pharmaceuticals's other current liabilities for the quarter that ended in Mar. 2024 was $31.5 Mil.

Ionis Pharmaceuticals's quarterly other current liabilities increased from Sep. 2023 ($43.7 Mil) to Dec. 2023 ($67.7 Mil) but then declined from Dec. 2023 ($67.7 Mil) to Mar. 2024 ($31.5 Mil).

Ionis Pharmaceuticals's annual other current liabilities increased from Dec. 2021 ($38.8 Mil) to Dec. 2022 ($49.2 Mil) and increased from Dec. 2022 ($49.2 Mil) to Dec. 2023 ($67.7 Mil).

Ionis Pharmaceuticals Other Current Liabilities Historical Data

The historical data trend for Ionis Pharmaceuticals's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Other Current Liabilities Chart

Ionis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Liabilities

Get a 7-Day Free Trial

Ionis Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Current Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Ionis Pharmaceuticals Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Ionis Pharmaceuticals Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ionis Pharmaceuticals (LTS:0JDI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (LTS:0JDI) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

IONS:USA IONS:Mexico ISI:Germany

Address

2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website

https://www.ionispharma.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Ionis Pharmaceuticals (LTS:0JDI) Headlines

No Headlines